Seredigm

Seredigm is a biotechnology company pioneering a novel approach to targeted protein degradation (TPD) through its proprietary Sere-D platform. The company focuses on serine-dependent degradation mechanisms, which allow for the targeting of disease-causing proteins that lack traditional binding pockets or are otherwise difficult to drug. Founded by Dr. David Bredt, a former R&D leader at Janssen and Eli Lilly, Seredigm aims to address significant unmet needs in oncology and neurodegenerative diseases. By leveraging specific serine residues, the company's small molecule degraders are designed to offer high selectivity and potency. Seredigm is currently in the pre-clinical stage and is backed by leading life science venture capital firms, including MPM BioImpact and Westlake Village BioPartners.